Table 1. Duration of first-line treatment in the variable-duration group by protocol version.

From HCV VL (IU/ml)	To HCV VL (IU/ml)	Days if randomised before 01/04/2017 (VUS1)	Days if randomised after 01/04/2017 (VUS2)
LLOQ	50,000	28	28
50,001	65,000	28	29
65,001	82,500	28	30
82,501	110,000	28	31
100,001	140,000	28	32
150,001	180,000	28	33
175,001	235,000	28	34
225,001	300,000	28	35
300,001	400,000	29	36
400,001	500,000	30	37
500,001	550,000	30	38
550,001	650,000	31	38
650,001	750,000	31	39
750,001	850,000	32	39
850,001	1,100,000	32	40
1,100,001	1,300,000	33	41
1,300,001	1,450,000	34	41
1,450,001	1,700,000	34	42
1,700,001	1,850,000	35	42
1,850,001	2,200,000	35	43
2,200,001	2,400,000	36	43
2,400,001	2,850,000	36	44
2,850,001	3,150,000	37	44
3,150,001	3,600,000	37	45
3,600,001	4,100,000	38	45
4,050,001	4,550,000	38	46
4,550,001	5,250,000	39	46
5,250,001	5,700,000	39	47
5,700,001	6,800,000	40	47
6,800,001	7,100,000	40	48
7,100,001	8,800,000	41	48
8,800,001	upwards	42	49

Note: VUS: variable ultra-short